MarketCap
Facebook
X
Telegram
QIAGEN N.V. EBITDA | QGEN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 660 M | 301 M | 615 M | 740 M | 845 M | 591 M | 205 M | 473 M | 370 M | 138 M | 214 M | 198 M | 98.8 M | 206 M | 126 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 845 M | 98.8 M | 385 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B |  USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Syneos Health
SYNH
|
650 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
-29.2 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
-793 K | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
-96.6 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
T2 Biosystems
TTOO
|
-48.8 M | - | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Bioventus
BVS
|
101 M | $ 13.0 | 1.39 % | $ 866 M | USA |
 |
DarioHealth Corp.
DRIO
|
-36.3 M | $ 6.75 | 2.31 % | $ 26.9 M | Israel |
 |
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-33.9 M | - | -61.36 % | $ 2.46 M | USA |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.69 | 1.45 % | $ 87.3 K | USA |
 |
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | USA |
|
Biodesix
BDSX
|
-22.2 M | $ 27.7 | 1.09 % | $ 209 M | USA |
 |
BioNano Genomics
BNGO
|
-23.8 M | $ 1.56 | 17.29 % | $ 8.49 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-33.1 M | $ 11.68 | 0.69 % | $ 123 M |  China |
 |
CareDx, Inc
CDNA
|
-15.8 M | $ 52.64 | 0.52 % | $ 2.81 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 82.7 | 0.1 % | $ 3.87 B | USA |
 |
Co-Diagnostics
CODX
|
-49.1 M | $ 1.14 | 2.7 % | $ 1.52 M | USA |
 |
Charles River Laboratories International
CRL
|
428 M | $ 272.88 | 0.59 % | $ 13.5 B | USA |
 |
Castle Biosciences
CSTL
|
-2.04 M | $ 35.5 | 6.16 % | $ 1.03 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 247.08 | 3.9 % | $ 27.4 B | USA |
 |
Meridian Bioscience
VIVO
|
70.9 M | - | - | $ 1.49 B | USA |
 |
Biomerica
BMRA
|
-5.24 M | $ 2.3 | 0.42 % | $ 6.7 M | USA |
 |
Fulgent Genetics
FLGT
|
-67 M | $ 21.28 | 3.05 % | $ 655 M | USA |
 |
Guardant Health
GH
|
-398 M | $ 175.65 | 4.65 % | $ 22 B | USA |
 |
ICON Public Limited Company
ICLR
|
826 M | $ 172.45 | 2.08 % | $ 13.5 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.51 B | $ 510.73 | 0.23 % | $ 41.1 B | USA |
 |
Danaher Corporation
DHR
|
5.44 B | $ 209.36 | 3.01 % | $ 149 B | USA |
 |
Illumina
ILMN
|
1.08 B | $ 222.29 | 6.76 % | $ 34.5 B | USA |
 |
IQVIA Holdings
IQV
|
3.33 B | $ 269.67 | 1.51 % | $ 46.4 B | USA |
 |
Brainsway Ltd.
BWAY
|
1.39 M | $ 13.46 | 0.14 % | $ 457 M | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
2.07 B | $ 323.97 | 2.75 % | $ 27 B | USA |
 |
Lantheus Holdings
LNTH
|
381 M | $ 100.73 | 0.41 % | $ 6.8 B | USA |
 |
DexCom
DXCM
|
1.16 B | $ 86.45 | 2.09 % | $ 33.7 B | USA |
 |
Medpace Holdings
MEDP
|
562 M | $ 620.48 | 4.21 % | $ 17.9 B | USA |
 |
Mettler-Toledo International
MTD
|
51.1 M | $ 1 330.4 | 3.47 % | $ 27.4 B | Schweiz |
 |
Myriad Genetics
MYGN
|
-334 M | $ 3.88 | 2.37 % | $ 359 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.72 M | $ 5.66 | 1.13 % | $ 4.45 M | USA |
 |
NeoGenomics
NEO
|
-79.8 M | $ 18.89 | 2.61 % | $ 2.42 B | USA |
 |
Neogen Corporation
NEOG
|
94.7 M | $ 12.25 | 2.51 % | $ 2.66 B | USA |
 |
National Research Corporation
NRC
|
30.2 M | $ 21.96 | 5.63 % | $ 492 M | USA |
 |
Natera
NTRA
|
-268 M | $ 350.78 | 2.63 % | $ 48 B | USA |
 |
OPKO Health
OPK
|
-25.8 M | $ 1.57 | 0.64 % | $ 1.18 B | USA |
 |
Pacific Biosciences of California
PACB
|
-541 M | $ 1.34 | 0.37 % | $ 402 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.55 B | $ 24.9 | 1.99 % | $ 23.6 B |  Niderland |
 |
Personalis
PSNL
|
-78 M | $ 16.1 | 0.31 % | $ 1.44 B | USA |